Arquivos Brasileiros de Cardiologia (Apr 2010)
Dosagem única de troponina cardíaca T prediz risco adverso na insuficiência cardíaca descompensada Dosificación única de troponina cardíaca T predice riesgo adverso en la insuficiencia cardiaca descompensada Single cardiac troponin T measurement predicts risk for adverse outcome in decompensated heart failure
Abstract
FUNDAMENTO: O aumento discreto de troponina cardíaca no sangue de pacientes com insuficiência cardíaca (IC) sugere que miofibrilas são degradadas no miocárdio e liberadas na circulação, refletindo um processo contínuo e progressivo de lesão do aparato contrátil. OBJETIVO: Correlacionar o nível sérico da troponina cardíaca-T (TnTc) à admissão hospitalar de pacientes com IC descompensada e o prognóstico. MÉTODOS: Foram incluídos 79 pacientes consecutivos, internados por IC descompensada, com FEVE 2,5 mg%, insuficiência hepática ou doenças neuromusculares. RESULTADOS: Detectou-se TnTc elevada (>0,02 ng/ml) em 37 pacientes (46,84%). A mortalidade global foi de 35,4%. Nos grupos TnTc elevada e TnTc baixa (FUNDAMENTO: El aumento discreto de troponina cardíaca en la sangre de pacientes con insuficiencia cardiaca (IC) sugiere que miofibrillas se degraden en el miocardio y se liberen en la circulación, lo que refleja un proceso continuo y progresivo de lesión del aparato contráctil. OBJETIVO: Correlacionar el nivel sérico de la troponina cardíaca-T (TnTc) al ingreso hospitalario de pacientes con IC descompensada y el pronóstico. MÉTODOS: Se incluyó a 79 pacientes consecutivos, internados por IC descompensada, con FEVI 2,5 mg%, insuficiencia hepática o enfermedades neuromusculares. RESULTADOS: Se detectó TnTc elevada (> 0,02 ng/ml) en 37 pacientes (46,84%). La mortalidad global fue del 35,4%. En los grupos TnTc elevada y TnTc baja (BACKGROUND: The slight increase in cardiac troponin in the blood of patients with heart failure (HF) suggests that myofibrils are degraded in the myocardium and released in the circulation, reflecting a continuous and progressive injury process in the contractile system. OBJECTIVE: To correlate the serum levels of cardiac troponin T (TnT) at the hospital admission of patients with decompensated HF and prognosis. METHODS: A total of 79 consecutive patients, hospitalized due to decompensated HF, with LVEF 2.5 mg%, liver failure, or neuromuscular diseases. RESULTS: High levels of TnTc (>0.02 ng/ml) were detected in 37 patients (46.84%). The global mortality was 35.4%. In the groups with high TnT and low TnT levels (<0.02 ng/ml) there were, respectively, 19 versus 9 deaths (RR=2.4; 95%CI 1.24-4.63; p=0.011), 5 versus 4 heart transplants (RR=1,42; 95%CI 0.41-4.89; p=0.73), 11 versus 7 patients needed IV inotropic agents (RR=1.78; 95%CI 0.77-4.12; p=0.26) and 14 versus 10 patients were re-hospitalized (RR=1.85; 95%CI 0.95-3.6; p=0.10). Mean troponin levels were significantly higher in those individuals who died (0.071±0,119 vs 0.032±0.046; p=0.004). At the multivariate analysis, the persistence of the third sound and the need for IV inotropic agents showed to be independent predictors of death; however, we observed a higher tendency towards mortality for patients presenting high TnT when compared to those with low troponin levels (HR=2.64; 95%CI 0.91-7.63; p=0.07). CONCLUSION: The single troponin measurement at hospital admission in patients with decompensated HF predicts adverse outcomes and should be considered at the early stratification of long-term morbimortality.
